<DOC>
	<DOCNO>NCT00002080</DOCNO>
	<brief_summary>Primary : To provide rifabutin HIV positive patient attempt prevent delay Mycobacterium avium Complex ( MAC ) infection daily dose rifabutin . Secondary : To characterize safety rifabutin monotherapy prevent delay MAC bacteremia HIV positive patient CD4 count = &lt; 200 .</brief_summary>
	<brief_title>Rifabutin Therapy Prevention Mycobacterium Avium Complex ( MAC ) Bacteremia HIV Positive Patients With CD4 Counts = &lt; 200 : Treatment IND Study</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
	<mesh_term>Rifabutin</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Any medication exception investigational drug available treatment IND , expand access , parallel track program . Patients must : Confirmed HIV infection . CD4 cell count &lt; = 200 cells/mm3 . No evidence disseminate MAC disease . Informed consent parent guardian 12 &lt; 18 year age . NOTE : Pregnant female may eligible . There study safety efficacy rifabutin pregnant woman . Rifabutin use pregnancy potential benefit justifies potential risk fetus . In addition , risk/benefit decision consider likelihood woman 's develop MAC receive prophylaxis . The risk develop MAC rise substantially woman CD4 count less 100 , although also develop woman high CD4 count . Women reproductive potential pregnant must use contraception . They encourage use mean oral contraceptive . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Known hypersensitivity rifabutin , rifampin , rifamycins . Current infection due MAC mycobacterial disease , complaint consistent tuberculosis . Concurrent Medication : Excluded : Other investigational drug exception available treatment IND , expand access , parallel track program . ( Licensed product prescribe unlabeled indication consider investigational . ) Patients follow prior condition exclude : Prior infection due MAC mycobacterial disease complaint consistent tuberculosis .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2003</verification_date>
	<keyword>Rifabutin</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Mycobacterium avium Complex</keyword>
	<keyword>Bacteremia</keyword>
</DOC>